Latest: Abzena Launches EpiScreen® 2.0 Immunogenicity Platform | Learn more
- About
- Main Menu
- Main Menu
- Leadership Team
- Our History
- Locations
- Capabilities
- Main Menu
- Main Menu
- Bioconjugates & Chemistry
- Biologics
- Resources
- Careers
- Contact
Reliable assays to characterize your product.
Your program will benefit from Abzena’s wealth of experience and expertise across a diverse range of modalities including conjugates, multi-specifics, fusions, fragments, agonist, and antagonist activities.
When it comes time to evaluate the immunogenic risk of your biopharmaceutical program, our newly enhanced EpiScreen 2.0 platform offers a comprehensive suite of assays that can predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.
Our unique, next-generation tool delivers a more advanced set of immune response measurements with the required sensitivity, plus detailed information on specificity and MoA to better inform the nature of immunogenicity risk and offers insights into how to mitigate this through protein engineering and formulation. To learn more, access the info sheet here.
To help understand your molecule in detail, we have an extensive panel of both target and effector cells together with a substantial in-house PBMC cell bank. Complementing this is a broad choice of assay platforms, including:
Access is latest info sheet on our newly enhanced EpiScreen 2.0 platform to learn more.
From bench to bedside, we are dedicated to ensuring quality excellence in everything we do.
We adapt our approach to shorten lead times and develop risk mitigations strategies to ensure your overall success in delivering vital medicines to patients.